As Boomer generates, the prevalence of polypharmacy, patients taking multiple medications to handle chronic conditions, is increasing. Almost 40% of older adults take five or more medications, a number that has tripled in the last two decades. While polypharmacy may be necessary, they are also significant drug events (ADE), with up to 30% of hospital admissions among older adults linked to complications related to medicines. However, when speaking with the leaders of the health system on how they handle patients in polypharmacy, they often focus on mitigating problems highlighting programs that drive adherence or describe certain medications.
But, in the current health ecosystem, where suppliers are lower and lower value contracts based on value (VBC), health systems, responsible care organizations (ACO) and pharmacy leaders must go beyond traditional approaches for medication management, which often focus too much on adherence and depress medications. While they ensure that patients take their medications correctly and avoid harmful interactions of medicines, they are important, a broader strategy is needed. The effective use of medications is not just about keeping patients along the way with their recipes, it is about using medications as a health tool for the whole person. Without this mentality, suppliers run the risk of missing critical factors that contribute to bad results, including complications induced by medications, redundant treatments and the overly overlooked underlying conditions.
Depressed is a necessary tool, but it is not the whole solution
Reflecting on conversations with more than 100 medical care organizations last year, a common topic emerged: A strong approach to depression. And it is not without a good reason. The research has suggested that up to 60% of older Americans can have a drug they do not need. In a study of more than 2000 older veterans with diabetes, researchers found that more than half were candidates to drop blood pressure or blood sugar control medications.
However, although depression cradle is an essential component of medication optimization, medication reduction is turned on without an exhaustive review of the patient’s health can be myopic. In fact, the investigation has shown that simply stopping mediations without a broader clinical strategy can lead to unioned damage, partly when it is done without careful monitoring.
Many suppliers see deprobation as a cost reduction measure or response to polypharmacy groups, but do not consult that stopping a medicine can increase dependence on another. For example, consider a patient who handles chronic pain at the bottom with long -term opioid therapy. Approximately time, that patient has also developed insomnia and anxiety, which are their medical attributes both to their underlying pain and to the possible side effects of medications. To help with their sleep disorders, a benzodiazepine is prescribed to the patient.
After a medication review, the medical care team decides depression of benzodiazepine due to Conerns on falls, cognitive impairment and dependence. However, they do not consider how to interrupt benzodiazepine will affect the patient’s ability to tolerate their chronic pain. Without benzodiazepine, the patient experiences sleep and anxiety, which leads to greater perception of pain. As a result, the use of opioids intensifies as the patient depends heavier heavy to deal with both the increase in pain and worship, increasing the risk of side effects related to opioids, including sedation, falls and respiratory depression.
This example illustrates why crib depression should not be an instinctive reaction to Conerns polypharmacy in the state of the head, it should be part of a tourist and patient -centered strategy that guarantees that medications work together to improve general health. But, understanding the risks of thesis in advance and developing a plan-special scale when suppliers are responsible for thousands of patients, it is an incredible challenge, one that is almost impossible on a scale without an axist.
Medication optimization focuses on holistic health and can improve value -based care (VBC) care
The true medication optimization also means assessing whether each medicine is appropriate, effective, aligned with the broader health objectives of the patient and will not be problematic in the long term.
For example, a patient with two blood pressure medications may seem well controlled, but their treatment could contribute silently to renal failure. Without a holistic medication review, just focusing on adhesion and/or describing in isolation may not consider this complication, creating gaps in care or simply health results.
Scenarios such as these are much more frequent than it might think that it is possible, and again, when a supplier (as specials of the populations of Trotea -the) can be an answer for thousands of patale at scale at scale.
A comprehensive medication management strategy is partially critical for suppliers operating under VBCs, where financial incentives are directly linked to patient results and cost containment. Bad medication management contributes to visits to the prevention emergency department, hospital re -enters and complications, all of which increases and negatively impact performance metrics on risk -based contracts.
To obtain success in value based on value, suppliers must go beyond traditional adhesion programs to medicines and ensure that prescribed treatments are committed in accepting the best health results and profitability. A holistic drug management strategy should include:
- Regular medication efficacy evaluations: not only for interactions but for the general impact on patient’s health.
- Evaluate the treatment objectives in an integral way, ensuring that the measurements not only handle the conditions but also avoid more complications.
- Proactive identification of risk interactions known drugs, including long -term possible damages, nutritional deficiencies and cognitive side effects.
- Levers Technology to synthesize fixed amounts of clinical data and identify more personalized medication settings.
The ability to optimize medication regimes proactively that reacts reactively to suppliers of announceable events positions for stronger financial and quality performance under value based on value.
Raising the standard of attention
For too long, medical care organizations have assumed that adherence programs and crib protocols were enough to handle polypharmacy. But optimizing measurements is not just about compliance, it is about ensuring that each recipe contributes to better patient health. Suppliers who do not adopt this mentality can be conditions of rigor in the role, but losing the biggest image of the patient’s well -being.
When going beyond adherence and pharmacological interactions, a holistic approach, based on results, health systems and suppliers can redefine how medication is used, not as a rigid protocol, but as a dynamic tool and patient focused to achieve better health. The future of medication management does not lie in reducing pills or adhesion counts alone, but in the use of each medication decision to boost measurable and significant improvements in the patient’s results.
Photo: Stas_v, Getty Images
Adva Tzuk Onn, MD, is the medical director of Feelbetter and a doctor with approximately 20 years of experience in geriatric and family medicine, since she has directed innovative models of care in the main Israeli HMO. She is co -founder of the Society of Lifestyle Medicine, a certified motivating interview trainer and active member of the Israeli Society of Healthtech. Dr. Tzuk Onn obtained her doctor’s degree from the Faculty of Medicine of the University of Tel Aviv.
This publication appears through Medical influencers program. Anyone can publish their perspective on business and innovation in medical care in Medcity News through influential people of Medcy. Click here to find out how.
